ClinicalTrials.gg
TerminatedNCT00471068Updated Apr 11, 2012Results posted

Study of Travatan and Cosopt in Primary Open-Angle Glaucoma or Ocular Hypertension

A Phase 4 interventional study of Travatan and Cosopt in Open-angle Glaucoma and Ocular Hypertension, sponsored by Alcon Research. Terminated at 1 site in Portugal. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-04-11.

Sponsored by Alcon Research (part of Alcon) · Phase 4, Interventional, and Treatment

Why this study was terminated
Question raised by Ethics Committee

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 46 studies testing travoprost in Glaucoma, Open-Angle — 2 open to participants now, 3 under way, 1 of them phase 3. Travoprost · Glaucoma, Open-Angle.

Enrollment
40th of 45
46 · median 135
Started
2007
with 4 others
Phase 4
22 of 46
2 open now
Registered
10th of 46
by date
Lead sponsor
29 of 46
Alcon Research

Among the 46 studies testing travoprost in Glaucoma, Open-Angle, this one is the 40th largest by enrollment of the 45 interventional ones that give a count, is one of 5 that started in 2007, is one of 22 in phase 4, and was the 10th registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

2 of the 46 studies testing travoprost in Glaucoma, Open-Angle are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About travoprost

Travoprost: first FDA approval 2001 (TRAVATAN), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies testing travoprost in Glaucoma, Open-Angle, or all of them as a file.
02

Study summary

To compare the efficacy and safety in patients treated with travoprost versus dorzolamide/timolol maleate combination in patients with open-angle glaucoma or ocular hypertension

03

Conditions studied

  • Open-angle Glaucoma
  • Ocular Hypertension
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient with open-angle glaucoma or ocular hypertension

Exclusion criteria

Exclusion Criteria:

  • By Age
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
46 participants (actual)

Study arms

  • Experimental
    Travatan

    Travatan: 6 weeks treatment with Travatan (travoprost 40 mg/ml eye drops, solution) once daily at 08:00 and placebo (timolol vehicle) once daily at 20:00 in the affected eye(s)

    Drug: Travatan · Drug: Placebo (Timolol Vehicle)

  • Active comparator
    Cosopt

    treatment period of 6 weeks with Cosopt (dorzolamide 20 mg/ml and timolol maleate 5 mg/ml eye drops, solution) twice daily at 08:00 and 20:00 in the affected eye(s)

    Drug: Cosopt

Interventions

  • Travatan: 6 weeks treatment with Travatan (travoprost 40 mg/ml eye drops, solution) once daily at 08:00 and placebo (timolol vehicle) once daily at 20:00 in the affected eye(s)

  • DrugCosopt

    treatment period of 6 weeks with Cosopt (dorzolamide 20 mg/ml and timolol maleate 5 mg/ml eye drops, solution) twice daily at 08:00 and 20:00 in the affected eye(s)

  • DrugPlacebo (Timolol Vehicle)

    Travatan group: 6 weeks treatment with Travatan (travoprost 40 mg/ml eye drops, solution) once daily at 08:00 and placebo (timolol vehicle) once daily at 20:00 in the affected eye(s)

06

What researchers measure

Primary outcomes

  1. Intaocular Pressure (IOP) Mean Change After 6 Weeks of Treatment

    IOP measured at week 6 minus IOP measured at baseline

    Time frame: At week 0 and week 6

07

Results

Posted Jan 8, 2010
Limitations and caveats
Sample size smaller than the one defined by the protocol

Participant flow

Recruitment period: from 13-03-2007 to 30-11-2007 Recruitment restarted on 27-03-2008 to 27-05-2008 First patient first visit: 19-03-2007 Last patient last visit: 29-05-2008

Participant flow — Overall Study
MilestoneTravatanCosopt
Started2125
Completed2024
Not completed11

Outcome measures

PrimaryIntaocular Pressure (IOP) Mean Change After 6 Weeks of Treatment

IOP measured at week 6 minus IOP measured at baseline

Time frame:
At week 0 and week 6
Reported as:
Mean · millimeters mercury (mm Hg)
Intaocular Pressure (IOP) Mean Change After 6 Weeks of Treatment
millimeters mercury (mm Hg)TravatanCosopt
Intaocular Pressure (IOP) Mean Change After 6 Weeks of Treatment-4.57 ± 1.62-4.08 ± 2.50

Adverse events

Collected over Run-in (2-4 weeks) + treatment period (6 weeks). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Travatan—0/21 (0%)2/21 (9.5%)
Cosopt—1/25 (4%)3/25 (12%)
Most frequent serious events
Most frequent serious events
EventTravatanCosopt
Inguinal hernia surgerySurgical and medical procedures0/211/25
Most frequent other events
Most frequent other events
EventTravatanCosopt
Ocular pruritusEye disorders1/211/25
Redness eyeEye disorders1/210/25
FluInfections and infestations0/211/25
Ocular discomfortEye disorders0/211/25

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)TravatanCosoptTotal
<=18 years000
Between 18 and 65 years101626
>=65 years11920
Sex: Female, Male
Sex: Female, Male(Participants)TravatanCosoptTotal
Female141024
Male71522
08

Study locations

1 site
  • Coimbra
    Coimbra, 3000354, Portugal
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2007 and a primary completion of Aug 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2010, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2007
First posted
May 9, 2007
Start
Mar 2007
Primary completionActual
Aug 2008
Results first posted
Jan 8, 2010
Last update
Apr 11, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 11, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00471068
Lead sponsor
Alcon Research
Responsible party
Sponsor
First posted
May 9, 2007
Start date
Mar 2007
Primary completion
Aug 2008
Results posted
Jan 8, 2010
Last update
Apr 11, 2012

Study contacts

Anna Grau
study director · Alcon Research

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Travoprost

Start the discussion